ReWalk Robotics Ltd. (Nasdaq: RWLK) (‚ÄúReWalk‚Äù or the ‚ÄúCompany‚Äù) today announced that it has priced its underwritten public offering of 6,857,000 ordinary shares at a price to the public of $1.05 per ordinary share. All of the ordinary shares in the offering are to be sold by ReWalk.
National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation (NASDAQ: NHLD), is acting as sole book-running manager of the offering. ReWalk has granted the underwriter a 45-day option to purchase up to 1,028,550 ordinary shares sold in the public offering on the same terms and conditions. The offering is expected to close on November 21, 2017, subject to customary closing conditions.
ReWalk intends to use the net proceeds from the offering for (i) sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage and (ii) research and development costs related to developing its lightweight ‚Äúsoft suit‚Äù exoskeleton technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk.
The offering is being made under an effective registration statement on file with the Securities and Exchange Commission (the ‚ÄúSEC‚Äù). Copies of the preliminary prospectus may be obtained from National Securities Corporation, Attention: Marguerite Rogers, 200 Vesey Street, 25th Floor, New York, NY 10281, by telephone at (212) 417-8227, or by email at [email protected] The preliminary prospectus is also available on the SEC‚Äôs website at www.sec.gov. The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC and made available on the SEC‚Äôs website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities discussed in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About¬†ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.
ReWalk¬Æ is a registered trademark of ReWalk Robotics Ltd. in Israel.
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk‚Äôs future performance and, in some cases, may be identified by words like ‚Äúanticipate,‚Äù ‚Äúassume,‚Äù ‚Äúbelieve,‚Äù ‚Äúcontinue,‚Äù ‚Äúcould,‚Äù ‚Äúestimate,‚Äù ‚Äúexpect,‚Äù ‚Äúintend,‚Äù ‚Äúmay,‚Äù ‚Äúplan,‚Äù ‚Äúpotential,‚Äù ‚Äúpredict,‚Äù ‚Äúproject,‚Äù ‚Äúfuture,‚Äù ‚Äúwill,‚Äù ‚Äúshould,‚Äù ‚Äúwould,‚Äù ‚Äúseek‚Äù and similar terms or phrases. The forward-looking statements contained in this press release are based on management‚Äôs current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk‚Äôs control. Important factors that could cause ReWalk‚Äôs actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk‚Äôs expectations regarding future growth, including its ability to increase sales in its existing geographic markets, expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk‚Äôs management for the financial statements for the third quarter of 2017 and for fiscal 2016, and the opinion of ReWalk‚Äôs auditors in their report on the Company‚Äôs financial statements for fiscal 2016, that there are substantial doubts as to ReWalk‚Äôs ability to continue as a going concern; ReWalk‚Äôs ability to maintain and grow its reputation and the market acceptance of its products; ReWalk‚Äôs ability to achieve reimbursement from third-party payors for its products; ReWalk‚Äôs expectations as to its clinical research program and clinical results; ReWalk‚Äôs expectations as to the results of, and the Food and Drug Administration‚Äôs potential regulatory developments with respect to, ReWalk‚Äôs mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk‚Äôs initial public offering;¬† ReWalk‚Äôs ability to repay its secured indebtedness; ReWalk‚Äôs ability to improve its products and develop new products; ReWalk‚Äôs ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk‚Äôs ability to gain and maintain regulatory approvals; ReWalk‚Äôs ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk‚Äôs shareholders or restrict its business; ReWalk‚Äôs ability to use effectively the proceeds of offerings of securities; ReWalk‚Äôs ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market price of ReWalk‚Äôs ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk‚Äôs ability to comply with the continued listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk‚Äôs compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events on ReWalk‚Äôs ability to market and sell its products; and other factors discussed under the heading ‚ÄúRisk Factors‚Äù in ReWalk‚Äôs Annual Report on Form 10-K for the year ended December 31, 2016, as amended, filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk‚Äôs actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.